Neurogene Secures FDA Breakthrough Designation for Rett Therapy After Phase 1/2 Data
Neurogene received FDA Breakthrough Therapy designation for NGN-401, its investigational gene therapy for Rett syndrome, based on interim Phase 1/2 data showing clinically meaningful improvements across multiple functional domains. The company plans to complete dosing in its Embolden registrational trial by Q2 2026 and present additional interim data in mid-2026.
1. FDA Grants Breakthrough Designation
The FDA has awarded Breakthrough Therapy designation to NGN-401 for Rett syndrome, recognizing clinically meaningful improvements from interim Phase 1/2 trial data. This status enables expedited development pathways, including Priority Review eligibility and rolling Biologics License Application submissions.
2. Positive Interim Trial Data
Interim results from the Phase 1/2 study demonstrated functional gains across multiple domains in patients with Rett syndrome, validating Neurogene’s proprietary EXACT transgene regulation technology for delivering the full-length human MECP2 gene.
3. Development Timeline and Next Steps
Neurogene expects to complete dosing in its Embolden registrational trial by Q2 2026 and will present additional interim clinical data in mid-2026, positioning the program for accelerated regulatory review and potential early market entry.